10x Genomics & Single Cell Sequencing

Former Director at 10x Genomics

Print

Executive Bio

Former Director at 10x Genomics

The executive has over 22 years experience in biotech and is the Former Director at 10x Genomics, responsible of managing the top pharma customer accounts.Read more

View Profile Page

Interview Transcript

... (transcript preview, sign up to read more) ...

80 plus.

... (transcript preview, sign up to read more) ...

That's in line. I wish I knew what they were selling it at, but it is impressive they pre-sold 100. I've always believed 10X was operating from a position of strength and playing offense in single cell, but they are playing a different sport with spatial. NanoString beat them to market, so did Vizgen eventually, and Resolve is making noise. This is a crowded, competitive landscape which includes Akoya, so if that instrument is going to be expensive, far less customers will buy multiple platforms. In some ways, it was a race to lock in the heavy hitter customers. I suspect those 100 instruments were offered at deep discounts to ensure their instrument was on the floor and not Vizgen's. That instrument is not currently available so they probably sacrificed margin to get share, otherwise they would miss the boat because the launch is way behind schedule.

... (transcript preview, sign up to read more) ...

Sign up to read the full interview and hundreds more.

Audio

10x Genomics & Single Cell Sequencing(December 8, 2022)

00:00
00:00
Sign up to listen to the full interview and hundreds more.

PARTNER

Speak to Executive

Join waiting list for IP Partner
Did you like this article ?